BioCryst Pharmaceuticals
BCRX
#4496
Rank
C$3.58 B
Marketcap
C$14.11
Share price
0.40%
Change (1 day)
15.07%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of March 2026 : C$1.16 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is C$1.16 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2026)

Total debt by year

Year Total debt Change
2025-12-31C$0.60 B-48.21%
2024-12-31C$1.16 B6.04%
2023-12-31C$1.09 B8.78%
2022-12-31C$1.00 B33.08%
2021-12-31C$0.75 B112.14%
2020-12-31C$0.35 B222.34%
2019-12-31C$0.11 B31.28%
2018-12-31C$84.21 M22.41%
2017-12-31C$68.79 M-4.71%
2016-12-31C$72.19 M72.45%
2015-12-31C$41.86 M20.25%
2014-12-31C$34.81 M9.02%
2013-12-31C$31.93 M7.05%
2012-12-31C$29.83 M-2.24%
2011-12-31C$30.51 M
2000-12-31C$0.01 M
1997-12-31C$0.14 M-65.23%
1996-12-31C$0.41 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Gilead Sciences
GILD
C$31.46 B 2,611.53%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$35.81 B 2,986.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
C$1.47 B 26.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$0.97 B-15.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
C$0.41 B-63.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
C$2.7 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
C$2.12 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
C$13.31 M-98.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
C$0.94 B-18.91%๐Ÿ‡บ๐Ÿ‡ธ USA